Search research articles
Contact Us
Filters
Showing results (101-110 of 277) with videos related to
Page
of 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2014
Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy
Prasanth Ganesan, Siraj M Ali, Kai Wang, et al.
The Oncologist
|
January 25, 2021
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
Apostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, et al.
Oncotarget
|
June 27, 2013
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
Jennifer Wheler, Gerald Falchook, Apostolia M Tsimberidou, et al.
Oncology
|
September 21, 2013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
Ahmed O Kaseb, Mohamed Shama, Ibrahim Halil Sahin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 4, 2014
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer
Apostolia M Tsimberidou, Alexandra M Adamopoulos, Yang Ye, et al.
Oncoscience
|
January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Gerald S Falchook, Aung Naing, Jennifer J Wheler, et al.
Oncotarget
|
July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutations
Rabih Said, Yang Ye, David S Hong, et al.
Oncotarget
|
May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
Rabin Said, David S Hong, Carla L Warneke, et al.
Journal for Immunotherapy of Cancer
|
December 20, 2017
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg, David S Hong, Amini Behrang, et al.
Page
of 28
Search research articles
Search
Showing results (101-110 of 277) with videos related to
Sort By:
Page
of 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2014
Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy
Prasanth Ganesan, Siraj M Ali, Kai Wang, et al.
The Oncologist
|
January 25, 2021
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
Apostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, et al.
Oncotarget
|
June 27, 2013
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
Jennifer Wheler, Gerald Falchook, Apostolia M Tsimberidou, et al.
Oncology
|
September 21, 2013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
Ahmed O Kaseb, Mohamed Shama, Ibrahim Halil Sahin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 4, 2014
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer
Apostolia M Tsimberidou, Alexandra M Adamopoulos, Yang Ye, et al.
Oncoscience
|
January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Gerald S Falchook, Aung Naing, Jennifer J Wheler, et al.
Oncotarget
|
July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutations
Rabih Said, Yang Ye, David S Hong, et al.
Oncotarget
|
May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
Rabin Said, David S Hong, Carla L Warneke, et al.
Journal for Immunotherapy of Cancer
|
December 20, 2017
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg, David S Hong, Amini Behrang, et al.
Page
of 28